Program
nelitolimod
Also written as “SD-101”, “SD-101 Dermal Cream (6%)” and “SD-101-6.0 cream”.
Its studies are mostly in Epidermolysis Bullosa · Carcinoma, Hepatocellular · Uveal Melanoma · Melanoma · Lymphoma, B-Cell, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 40 open or running | phase 3since Feb 13, 2015 | Dec 12, 2013 | none ahead |
| Sanofi | 40 open or running | phase 2since Oct 13, 2014 | Jan 11, 2008 | none ahead |
| TriSalus Life Sciences | 31 open or running | phase 2since Jan 21, 2022 | Jun 2, 2021 | Sep 2027phase 1 · NCT05607953 |
| Paradigm Therapeutics | 22 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | May 17, 2027phase 3 · NCT07482787 |
| Merck | 10 open or running | phase 1since Apr 4, 2016 | Apr 4, 2016 | none ahead |
Also a collaborator on its studies: synteract-inc and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2008First study: phase 1 study in HealthyNew to SanofiSanofi · NCT00599001 · 26 enrolled · United States
- Jan 14, 2009Phase 1 study in Hepatitis C, ChronicSanofi · NCT00823862 · 34 enrolled · Poland
- Dec 12, 2013BioMarin Pharmaceutical's first study: phase 2 study in Epidermolysis BullosaNew to BioMarin PharmaceuticalBioMarin Pharmaceutical · NCT02014376 · 48 enrolled · United States
- Mar 12, 2014Phase 2 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02090283 · 42 enrolled · United States
- Oct 13, 2014Phase 2 study in Lymphoma, B-CellSanofi · NCT02266147 · 29 enrolled · United States
- Feb 13, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02384460 · 169 enrolled · United States, Australia, Austria and more
- Jul 28, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02670330 · 152 enrolled · United States, Australia, Austria and more
- Jul 30, 2015Phase 2 study in MelanomaSanofi · NCT02521870 · 241 enrolled · United States, Australia, Germany and more
- Apr 4, 2016Merck's first study: phase 1 study in NeoplasmsNew to MerckMerck · NCT02731742 · 14 enrolled
- Jun 2, 2021TriSalus Life Sciences's first study: phase 1 study in Uveal MelanomaNew to TriSalus Life SciencesTriSalus Life Sciences · NCT04935229 · 67 enrolled · United States
- Jan 21, 2022Phase 2 study in Carcinoma, HepatocellularTriSalus Life Sciences · NCT05220722 · 23 enrolled · United States
- Oct 19, 2022Phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953 · 60 enrolled · United States
- Mar 4, 2026Paradigm Therapeutics's first studies: 2 phase 3 studies in Epidermolysis BullosaNew to Paradigm TherapeuticsParadigm Therapeutics · NCT07482813, NCT07482787
Ahead
- May 17, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482787
- Sep 2027Primary completion: phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953
- Sep 19, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482813
TargetBeta
“A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities”NCIt, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07482813Epidermolysis Bullosa | 3 | Not yet recruiting | Paradigm Therapeutics | Sep 19, 2027 | 80 |
| NCT07482787Epidermolysis Bullosa · United States | 3 | Recruiting | Paradigm Therapeutics | May 17, 2027 | 80 |
| NCT05607953Locally Advanced Pancreatic Adenocarcinoma · United States | 1 | Active, not recruiting | TriSalus Life Sciences | Sep 2027 | 60 |
| NCT05220722Carcinoma, Hepatocellular · United States | 2 | Terminated | TriSalus Life Sciences | Jul 31, 2024 | 23 |
| NCT04935229Uveal Melanoma · United States | 1 | Terminated | TriSalus Life Sciences | Jul 17, 2024 | 67 |
| NCT02731742Neoplasms | 1 | Terminated | Merck | Jan 8, 2018 | 14 |
| NCT02521870Melanoma · United States, Australia, Germany and more | 2 | Terminated | Sanofi | Apr 2020 | 241 |
| NCT02670330Epidermolysis Bullosa · United States, Australia, Austria and more | 3 | Terminated | BioMarin Pharmaceutical | Sep 3, 2018 | 152 |
| NCT02384460Epidermolysis Bullosa · United States, Australia, Austria and more | 3 | Completed | BioMarin Pharmaceutical | Jul 5, 2017 | 169 |
| NCT02266147Lymphoma, B-Cell · United States | 2 | Terminated | Sanofi | Apr 2017 | 29 |
| NCT02090283Epidermolysis Bullosa · United States | 2 | Terminated | BioMarin Pharmaceutical | Sep 14, 2018 | 42 |
| NCT02014376Epidermolysis Bullosa · United States | 2 | Completed | BioMarin Pharmaceutical | Jun 24, 2014 | 48 |
| NCT00823862Hepatitis C, Chronic · Poland | 1 | Completed | Sanofi | Dec 2009 | 34 |
| NCT00599001Healthy · United States | 1 | Completed | Sanofi | Mar 2008 | 26 |
How it is read
Names in the registry
- “SD-101”, 7 entries
- “SD-101 Dermal Cream (6%)”, 3 entries
- “SD-101-6.0 cream”, 2 entries
- “SD-101(1)”, 1 entry
- “SD-101(2)”, 1 entry
Conditions, from the studies’ own filings
- Epidermolysis Bullosa, 6 studies
- Carcinoma, Hepatocellular, 1 study
- Uveal Melanoma, 1 study
- Melanoma, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.